公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan | CHEN-HUA LIU ; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 41 | 41 | |
2005 | Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan | Lee S.-D.; Yu M.-L.; Cheng P.-N.; Lai M.-Y.; Chao Y.-C.; Hwang S.-J.; Chang W.-Y.; Chang T.-T.; Hsieh T.-Y.; CHUN-JEN LIU ; DING-SHINN CHEN | Journal of Viral Hepatitis | 78 | 70 | |
2019 | Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions | Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; SHIH-JER HSU ; CHEN-HUA LIU ; Huang C.-F.; Su C.-W.; Huang J.-F.; CHUN-JEN LIU ; JIA-HORNG KAO ; Chuang W.-L.; PEI-JER CHEN ; DING-SHINN CHEN | Journal of the Formosan Medical Association | 10 | 8 | |
2021 | Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan | Cheng P.-N.; Chen C.-Y.; Yu M.-L.; Lin C.-C.; Lin C.-Y.; Peng C.-Y.; Tseng K.-C.; Lo C.-C.; Tseng I.-H.; CHUN-JEN LIU | Journal of Microbiology, Immunology and Infection | 5 | 4 | |
2022 | Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial | Cheng P.-N.; CHUN-JEN LIU ; Chen C.-Y.; Tseng K.-C.; Lo C.-C.; Peng C.-Y.; Lin C.-L.; Chiu H.-C.; Chiu Y.-C.; PEI-JER CHEN | Clinical Gastroenterology and Hepatology | 7 | 7 | |
2020 | Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) | Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L. | The American journal of gastroenterology | 20 | 17 | |
2022 | Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals | Chen Y.-C.; Chang T.-S.; Chen C.-H.; Cheng P.-N.; Lo C.-C.; Mo L.-R.; Chen C.-T.; Huang C.-F.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Chen C.-Y.; Tseng K.-C.; Yu M.-L.; on behalf of TACR investigators | Viruses | 1 | 1 | |
2021 | Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan | Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Yu M.-L. | Liver International | 25 | 23 | |
2009 | HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during Adefovir dipivoxil therapy | Tseng K.-C.; Cheng P.-N.; Wu I.-C.; CHIN-KUO CHANG ; Chou A.-L.; Liu W.-C.; Chang T.-T. | Hepato-Gastroenterology | 5 | 5 | |
2021 | Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort) | Hsu W.-F.; Tsai P.-C.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 10 | |
2022 | The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan | Lin C.-L.; Tai C.-M.; Huang J.-F.; CHUN-JEN LIU ; Chen H.-F.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Wang C.-C.; Weng S.-H.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 2 | 2 | |
2022 | Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR) | Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; SHIH-JER HSU ; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. | Clinical Gastroenterology and Hepatology | 14 | 12 | |
2022 | Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan | Lo C.-C.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Chen C.-Y.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; Chuang W.-L.; Lin H.-C.; JIA-HORNG KAO ; Yu M.-L.; TACR investigators | Journal of the Formosan Medical Association | 3 | 0 | |
2020 | Limited drug–drug interaction of elbasvir/grazoprevir for chronic hepatitis C | CHUN-JEN LIU ; Tseng K.-C.; Lo C.-C.; Tseng I.-H.; Cheng P.-N. | Journal of the Formosan Medical Association | 3 | 2 | |
2021 | Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) | Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; CHUN-JEN LIU ; Yu M.-L. | Hepatology International | 4 | 5 | |
2021 | Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan | Hsieh M.-H.; Bair M.-J.; Tsai P.-C.; Tseng K.-C.; Lo C.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Yu M.-L.; Chuang W.-L.; T-COACH investigators | Journal of Gastroenterology and Hepatology (Australia) | 2 | 3 | |
2021 | Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan | Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU ; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; JIA-HORNG KAO ; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. | Scientific Reports | 9 | 5 | |
2020 | An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions | Huang C.-F.; Hung C.-H.; Cheng P.-N.; Bair M.-J.; Huang Y.-H.; JIA-HORNG KAO ; SHIH-JER HSU ; Lee P.-L.; Chen J.-J.; Chien R.-N.; Peng C.-Y.; Lin C.-Y.; Hsieh T.-Y.; Cheng C.-H.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Yu M.-L. | Journal of Infectious Diseases | 15 | 11 | |
2015 | Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients | Yang C.-C.; Tsai W.-L.; Su W.-W.; Huang C.-F.; Cheng P.-N.; Lo C.-C.; Tseng K.-C.; Mo L.-R.; Wang C.-H.; SHIH-JER HSU ; Lai H.-C.; Su C.-W.; CHUN-JEN LIU ; Peng C.-Y.; Yu M.-L. | PLoS ONE | 8 | 5 | |
2019 | Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study | CHEN-HUA LIU ; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 8 | 8 |